2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1180

Class V Lupus Nephritis Results in Significant Numbers of End Stage Renal Disease and Death in a Population-Based Registry

Epidemiology and Public Health - Poster II

9:00AM-11:00AM: Abstract Number: 1349

Clinical Analysis of Hypertrophic Pachymeningitis

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1633

Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1936

Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1368

Clinical Course of Juvenile Dermatomyositis Presenting As Skin Predominant Disease

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1357

Clinical Description of Patients with Cytoplasmic Discrete Speckles on Indirect Immunofluorescence on HEp-2 Cells in a Universitary Hospital

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1954

Clinical Features and Long Term Outcome of 105 Patients of Granulomatosis with Polyangiitis: A Single Centre Experience from North India

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1924

Clinical Features and Outcome in Patients with Elderly Onset ANCA Associated Vasculitis

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1316

Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect

Infection-related Rheumatic Disease - Poster

9:00AM-11:00AM: Abstract Number: 1546

Clinical Features at the Onset of Lymphoproliferative Disorder in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1801

Clinical Implications of Persistent Sinus Tachycardia in Systemic Lupus Erythematous: A Retrospective Study

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1330

Clinical Presentations of Relapsing Polychondritis: More Than a Swollen Ear

Miscellaneous Rheumatic and Inflammatory Diseases - Poster II

9:00AM-11:00AM: Abstract Number: 1603

Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1136

Clinician Training in Motivational Communication Skills: The Impact of the Language of Change Program Among Rheumatologists from Across Canada

Education - Poster

9:00AM-11:00AM: Abstract Number: 1227

Clinician-Led Development of a Standardised Term Set for Rheumatic and Musculoskeletal Disorders Allows Easy Creation of Large-Scale ICD-10 and Snomed CT Mapped Datasets from Routinely Collected Clinical Data

Health Services Research - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].